Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:2957-2968
Published online before print May 21, 2007, doi: 10.1161/CIRCULATIONAHA.106.670026
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
115/23/2957    most recent
CIRCULATIONAHA.106.670026v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zakrzewicz, A.
Right arrow Articles by Eickelberg, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zakrzewicz, A.
Right arrow Articles by Eickelberg, O.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Nucleotide
*Protein*UniGene
*Genetics Home Reference
Medline Plus Health Information
*Pulmonary Hypertension
Related Collections
Right arrow Remodeling
Right arrow Smooth muscle proliferation and differentiation
Right arrow Pulmonary circulation and disease
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Other Vascular biology

(Circulation. 2007;115:2957-2968.)
© 2007 American Heart Association, Inc.


Vascular Medicine

Receptor for Activated C-Kinase 1, a Novel Interaction Partner of Type II Bone Morphogenetic Protein Receptor, Regulates Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension

Anna Zakrzewicz, PhD; Matthias Hecker, MD; Leigh M. Marsh, PhD; Grazyna Kwapiszewska, PhD; Bozena Nejman, MS; Lu Long, MD, PhD; Werner Seeger, MD; Ralph T. Schermuly, PhD; Nicholas W. Morrell, MD, FRCP; Rory E. Morty, PhD; Oliver Eickelberg, MD

From the Department of Medicine II (A.Z., M.H., L.M.M., G.K., B.N., W.S., R.T.S., R.E.M., O.E.), University of Giessen Lung Center, Justus Liebig University Giessen, Giessen, Germany, and Department of Medicine (L.L., N.W.M.), University of Cambridge School of Clinical Medicine, Addenbrooke’s and Papworth Hospitals, Cambridge, UK.

Correspondence to Oliver Eickelberg, MD, University of Giessen Lung Center, Department of Medicine II, Aulweg 123, Room 6–11, D-35392 Giessen, Germany. E-mail oliver.eickelberg{at}innere.med.uni-giessen.de

Received October 16, 2006; accepted March 29, 2007.

Background— Pulmonary arterial hypertension (PAH) is characterized by selective elevation of pulmonary arterial pressure. The pathological hallmark of PAH is the narrowing of pulmonary arterioles secondary to endothelial cell dysfunction and smooth muscle cell proliferation. Heterozygous mutations in BMPR2, encoding the type II bone morphogenetic protein receptor (BMPRII), were identified in PAH, suggesting that alterations to BMPRII function are involved in disease onset and/or progression.

Methods and Results— We identified the receptor for activated C-kinase (RACK1) as a novel interaction partner of BMPRII by yeast 2-hybrid analyses using the kinase domain of BMPRII as a bait. Glutathione-S-transferase pull-down and coimmunoprecipitation confirmed the interaction of RACK1 with BMPRII in vitro and in vivo. RACK1–BMPRII interaction was reduced when kinase domain mutations occurring in patients with PAH were introduced to BMPRII. Immunohistochemistry of lung sections from PAH and control patients and immunofluorescence analysis of primary pulmonary arterial smooth muscle cells demonstrated colocalization of BMPRII and RACK1 in vivo. Quantitative reverse-transcription polymerase chain reaction and Western blot analysis showed significant downregulation of RACK1 expression in the rat model of monocrotaline-induced PAH but not in pulmonary arterial smooth muscle cells from PAH patients. Abrogation of RACK1 expression in pulmonary arterial smooth muscle cells led to decreased Smad1 phosphorylation and increased proliferation, whereas overexpression of RACK1 led to increased Smad1 phosphorylation and decreased proliferation.

Conclusions— RACK1, a novel interaction partner of BMPRII, constitutes a new negative regulator of pulmonary arterial smooth muscle cell proliferation, suggesting a potential role for RACK1 in the pathogenesis of PAH.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
CirculationHome page
G. Kwapiszewska, M. Wygrecka, L. M. Marsh, S. Schmitt, R. Trosser, J. Wilhelm, K. Helmus, B. Eul, A. Zakrzewicz, H. A. Ghofrani, et al.
Fhl-1, a New Key Protein in Pulmonary Hypertension
Circulation, September 9, 2008; 118(11): 1183 - 1194.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K.-H. Hong, Y. J. Lee, E. Lee, S. O. Park, C. Han, H. Beppu, E. Li, M. K. Raizada, K. D. Bloch, and S. P. Oh
Genetic Ablation of the Bmpr2 Gene in Pulmonary Endothelium Is Sufficient to Predispose to Pulmonary Arterial Hypertension
Circulation, August 12, 2008; 118(7): 722 - 730.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. B. Yu, D. Y. Deng, H. Beppu, C. C. Hong, C. Lai, S. A. Hoyng, N. Kawai, and K. D. Bloch
Bone Morphogenetic Protein (BMP) Type II Receptor Is Required for BMP-mediated Growth Arrest and Differentiation in Pulmonary Artery Smooth Muscle Cells
J. Biol. Chem., February 15, 2008; 283(7): 3877 - 3888.
[Abstract] [Full Text] [PDF]